(OSCR) Oscar Health - Ratings and Ratios

Oscar Health, Inc. is a pioneering healthcare technology company in the United States, revolutionizing the way health plans are offered to individuals, families, employees, and small group markets. By leveraging its cutting-edge +Oscar platform, the company empowers various stakeholders across the healthcare system. Additionally, its Campaign Builder platform serves as a sophisticated engagement and recommendation tool for providers and payors, while also offering reinsurance products to mitigate risk.

With its roots dating back to 2012 as Mulberry Health Inc., the company rebranded to Oscar Health, Inc. in January 2021, signaling a significant shift in its growth trajectory. Headquartered in New York, New York, Oscar Health has established itself as a key player in the Life & Health Insurance sub-industry, as classified by the GICS.

Analyzing the available and , we can infer that Oscar Healths stock has experienced significant fluctuations, with a 52-week high of $23.27 and a low of $11.60. The current price of $14.69 is below its 20-day SMA of $15.19, indicating a potential short-term downtrend. However, its 50-day SMA of $13.99 suggests a longer-term uptrend. With a market capitalization of $3.51 billion and a forward P/E ratio of 19.34, the company appears to be reasonably valued. Considering its RoE of 10.61%, Oscar Health demonstrates a decent return on equity.

Forecasting Oscar Healths stock performance, we can anticipate a potential rebound if the company continues to innovate and expand its offerings. With its +Oscar platform and Campaign Builder, Oscar Health is poised to capitalize on the growing demand for healthcare technology solutions. If the stock price breaks above its 20-day SMA of $15.19, it may target the 52-week high of $23.27. Conversely, a decline below the 50-day SMA of $13.99 could signal a further downturn. Based on the available data, a reasonable price target for OSCR could be around $18.00 in the next 6-12 months, representing a potential upside of 22.5% from current levels.